All In Biotech

Drug Trial Radar · NCT06847542

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

A Phase IIIb, Multicenter, Single-arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Nov 27, 2025

Primary completion

Nov 15, 2028

Study completion Nov 15, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Genentech, Inc.
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • Susvimo PDS ImplantDevice

    Ranizumab will be administered via a PDS implant per the schedule described in the arm.

  • RanibizumabDrug

    Participants will receive ranibizumab delivered through the PDS implant. Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 68 and 72, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 MetersTime frame: Baseline, Week 68, Week 72

Locations

64 sites in 13 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Kepler Universitätskliniken GmbH - Med Campus III

    Linz, Austria · Recruiting

  • Landesklinikum Mistelbach

    Mistelbach, Austria · Recruiting

  • Klaudianova Nemocnice - Mlada Boleslav;Ophtalmology dpt

    Mladá Boleslav, Czechia · Recruiting

  • Faculty Hospital Ostrava

    Ostrava, Czechia · Recruiting

  • Faculty Hospital Kralovske Vinohrady

    Prague, Czechia · Recruiting

  • Ustredni vojenska nemocnice

    Prague, Czechia · Recruiting

  • Aarhus Universitetshospital

    Aarhus N, Denmark · Recruiting

  • Rigshospitalet Glostrup

    Glostrup Municipality, Denmark · Recruiting

  • Hopital Edouard Herriot - CHU Lyon

    Lyon, France · Recruiting

  • Clinique Honore Cave

    Montauban, France · Recruiting

  • CHNO des Quinze Vingts

    Paris, France · Recruiting

  • CHU Poitiers - CHR La Miletrie

    Poitiers, France · Recruiting

  • CHU Strasbourg - Nouvel Hopital Civil

    Strasbourg, France · Recruiting

  • Institut Ophtalmologique De l Ouest Jules Verne

    Nantes, Paris, France · Recruiting

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany · Recruiting

  • Universitätkslinikum Düsseldorf, Augenklinik

    Düsseldorf, Germany · Recruiting

  • Universitätsmedizin Göttingen Georg-August-Universität

    Göttingen, Germany · Recruiting

  • Medizinische Hochschule Hannover, Klinik für Augenheilkunde

    Hanover, Germany · Recruiting

  • Universitätsmedizin Rostock

    Rostock, Germany · Recruiting

  • Universitätsklinikum Würzburg, Augenklinik und Poliklinik

    Würzburg, Germany · Recruiting

  • Attikon University General Hospital

    Chaïdári, Greece · Recruiting

  • University General Hospital of Heraklion

    Heraklon, Greece · Recruiting

  • University Hospital of Larissa

    Larissa, Greece · Recruiting

  • "G.Gennimatas" General Hospital of Athens

    Athens, Attica, Greece · Recruiting

  • Ospedale Monaldi - AORN dei Colli

    Naples, Campania, Italy · Recruiting

  • Azienda Ospedaliero - Universitaria di Ferrara - Arcispedale Sant'Anna, Sede Ospedale di Cona;UO di Clinica Oculistica

    Cona (Ferrara), Emilia-Romagna, Italy · Recruiting

  • Ospedale Isola Tiberina - Gemelli Isola;UOC Chirurgia Vitreoretinica

    Rome, Lazio, Italy · Recruiting

  • ASST SANTI PAOLO E CARLO - Presidio San Paolo;SC Oculistica

    Milan, Lombardy, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Ospedale Maggiore della Carità;S.C.D.U. Oftalmologia

    Novara, Piedmont, Italy · Recruiting

  • AOU Città della Salute e della Scienza di Torino

    Turin, Piedmont, Italy · Recruiting

  • A.O.U. Policlinico Paolo Giaccone;Oculistica

    Palermo, Sicily, Italy · Recruiting

  • Szpital sw. Lukasza

    Bielsko-Biala, Poland · Recruiting

  • Specjalistyczny O?rodek Okulistyczny Oculomedica

    Bydgoszcz, Poland · Recruiting

  • OFTALMIKA Sp. z o.o

    Bydgoszcz, Poland · Recruiting

  • Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA

    Gliwice, Poland · Recruiting

  • SP ZOZ Szpital Uniwersytecki w Krakowie Oddzia? Kliniczny Okulistyki i Onkologii Okulistycznej

    Krakow, Poland · Recruiting

  • Klinika Okulistyczna Jasne Błonia Sp. z o. o.

    Lódz, Poland · Recruiting

  • Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie;Klinika Chirurgii Siatkówki i Cia?a Szklistego

    Lublin, Poland · Recruiting

  • Centrum Diagnostyki i Mikrochirurgii Oka LENS

    Olsztyn, Poland · Recruiting

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.